Quartz·1 min read·medium
AstraZeneca's profit beat expectations as cancer drug sales powered growth
✦AI Summary
AstraZeneca reported second-quarter core earnings of $2.63 per share, exceeding analyst expectations of $2.48. The company's growth was primarily driven by strong sales in its oncology drug portfolio.
Core earnings per share rose to $2.63 in the second quarter, topping analyst expectations of $2.48, as the company held its full-year and 2030 outlooks
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in